BNT162 Vaccine

mRNA vaccine against SARS-CoV-2 developed by Pfizer and BioNTech.

Also Known As:

BNT 162A1; BNT 162B1; BNT 162B2; BNT 162C2; COVID 19 Vaccine Pfizer BioNTech; Covid-19 Vaccine, Pfizer; Pfizer Covid 19 Vaccine; Pfizer-BioNTech, COVID-19 Vaccine; Vaccine Pfizer-BioNTech, COVID-19; Vaccine, BNT162; Vaccine, Pfizer Covid-19; Abdavomeran; BNT-162A1; BNT-162B1; BNT-162B2; BNT-162C2; BNT162A1; BNT162B1; BNT162B2; BNT162C2; COVID-19 Vaccine Pfizer-BioNTech; Comirnaty; Pfizer Covid-19 Vaccine; Pidacmeran; Tozinameran

Networked: 2727 relevant articles (199 outcomes, 347 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Li, Xue: 18 articles (12/2022 - 01/2022)
2.	Wong, Ian Chi Kei: 16 articles (12/2022 - 01/2022)
3.	Lai, Francisco Tsz Tsun: 15 articles (12/2022 - 01/2022)
4.	Lustig, Yaniv: 15 articles (03/2022 - 01/2021)
5.	Chui, Celine Sze Ling: 14 articles (12/2022 - 01/2022)
6.	Wan, Eric Yuk Fai: 14 articles (12/2022 - 01/2022)
7.	Rahav, Galia: 14 articles (06/2022 - 01/2021)
8.	Chan, Esther Wai Yin: 13 articles (12/2022 - 01/2022)
9.	Wong, Carlos King Ho: 13 articles (12/2022 - 01/2022)
10.	Alroy-Preis, Sharon: 13 articles (10/2022 - 01/2021)

Related Diseases

1.	COVID-19 11/04/2021 - "BNT162b2 is highly efficacious against coronavirus disease 2019 (Covid-19) and is currently approved, conditionally approved, or authorized for emergency use worldwide. " 01/01/2022 - "Pfizer-BioNTech COVID-19 (BNT162b2) conferred a high level of protection against Covid-19 with a proven short-term safety profile. " 01/01/2021 - "Vaccination with either one dose of BNT162b2 or ChAdOx1-S was associated with a significant reduction in symptomatic covid-19 in older adults, and with further protection against severe disease. " 08/01/2022 - "Among adolescents, full vaccination with BNT162b2 offered considerable protection against SARS-CoV-2 infections over at least three months without substantial evidence of waning." 05/01/2022 - "These data support the benefit of broad BNT162b2 booster recommendations, as three doses confers comparable, if not better, protection against SARS-CoV-2 infections and hospital admission as was seen soon after receiving two doses. "
2.	Infections 09/23/2023 - "BNT162b2 was highly effective against infection, symptomatic infection, and hospitalization in Japan's older adult population aged ≥65 years during the Delta-predominant period." 08/01/2021 - "These results suggest that BNT162b2 is moderately to highly effective in reducing infectivity, via preventing infection and through reducing viral shedding. " 12/01/2021 - "No healthcare workers who were double vaccinated had a positive PCR test for SARS-CoV-2 during this study period confirming vaccination with Pfizer BioNTec BNT162b2 gives excellent protection against infection of this variant." 01/01/2023 - "In children aged 5 to 11 years, 2 doses of BNT162b2 provide moderate protection against symptomatic Omicron infection within 4 months of vaccination and good protection against severe outcomes. " 01/01/2023 - "We found that adolescents who received two BNT162b2 doses had significant protection against Omicron infection in the first three months following their second dose (VE = 54.5%, confidence interval [CI]: [17.8%-76.9%], p = .014) but no protection afterwards. "
3.	Neoplasms (Cancer) 08/01/2023 - "In conclusion, long-term humoral and cellular immune responses to BNT162b2 were impaired in patients with lymphoid malignancies." 08/01/2023 - "We investigated immune responses after three or four doses of BNT162b2 in patients with myeloid and lymphoid malignancies compared to controls, and identified risk factors for humoral and cellular nonresponse 1 year after first vaccination. " 07/14/2023 - "Our data suggest expansion of NK cell counts as the most noteworthy change in circulating lymphocytes after the third dose of tozinameran in cancer patients receiving PD-1/PD-L1-targeted agents. " 05/16/2023 - "(2) Objectives: 1. To determine the adverse effects associated with BNT162B2 vaccination in children and young adults with cancer. " 01/09/2023 - "Safety data regarding BNT162b2 in cancer patients (CPs) are scarce. "
4.	Breakthrough Infections 01/01/2023 - "Additionally, oncology patients' humoral immune response was significantly greater after breakthrough-infection than in response to the 4th dose of BNT162b2." 01/01/2022 - "We performed a single-center observational trial to monitor the mid- (3 months) and long-term (10 months) adaptive immune response and to document breakthrough infections (BTI) in healthcare workers (n = 84) upon BNT162b2 vaccination in a real-world setting. " 11/01/2023 - "The study cohort comprised 59 HT recipients aged 58 (49,65) years with breakthrough infections after three or four monovalent BNT162b2 doses; 41 (69.5%) were men. " 11/01/2023 - "Fifty-six participants without breakthrough infection (BI) (ChAdOx1/BNT162b2 group: N=27; BNT162b2 group: N=29) and 33 with BI were included. " 10/26/2023 - "Correlation between specific antibody response to wild-type BNT162b2 booster and the risk of breakthrough infection with omicron variants: Impact of household exposure in hospital healthcare workers."
5.	Myocarditis (Carditis) 05/01/2022 - "Larger studies are needed to determine whether an association between Pfizer-BioNTech COVID-19 vaccine and myocarditis exists." 01/01/2022 - "This study provides, for the first time, the importance of classical monocytes in the pathogenesis of myocarditis following BNT162b2 vaccination and presents the possibility that vaccination affects monocytes, further inducing their differentiation and infiltration into the heart." 11/01/2023 - "BNT162b2 immunization-related myocarditis in adolescents and consequent hospitalization: Report from a medical center." 06/01/2023 - "We detected increased carditis risks within 28 days after all three doses of BNT162b2 but the risk after the third doses were not higher than that of the second dose when compared with baseline period. " 06/01/2023 - "The SCCS detected increased carditis risks after BNT162b2: 4.48 (95%confidence interval [CI]:2.99-6.70] in 1-14 days and 2.50 (95%CI:1.43-4.38) in 15-28 days after first dose; 10.81 (95%CI:7.63-15.32) in 1-14 days and 2.95 (95%CI:1.82-4.78) in 15-28 days after second dose; 4.72 (95%CI:1.40-15.97) in 1-14 days after third dose. "

Related Drugs and Biologics

1.	Vaccines
2.	Messenger RNA (mRNA)
3.	2019-nCoV Vaccine mRNA-1273
4.	sinovac COVID-19 vaccine
5.	mRNA Vaccines
6.	COVID-19 Vaccines
7.	BNT162 Vaccine
8.	ChAdOx1 nCoV-19
9.	N-methyl-valyl-amiclenomycin (BA 2)
10.	BIBP COVID-19 vaccine

Related Therapies and Procedures

1.	Home Nursing (Nursing, Home)
2.	Therapeutics
3.	Long-Term Care
4.	Drug Therapy (Chemotherapy)
5.	Liver Transplantation